Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2019

View Archived Issues

A case study exploring a novel AKT1 fusion-driven cancer

Cutting out the middleman for MSI-high diagnosis

Drivers or drifters?

Recruitment ongoing in phase II study of I-131-1095 plus enzalutamide in patients with mCRPC

FDA grants IND permission to PrimeVax for use of U.S. Army's dengue virus to treat cancer

FibroGen initiates phase III study of pamrevlumab plus chemotherapy in pancreatic cancer

Phase II results presented for PT-2385 in patients with glioblastoma

First-in-human data presented for the bispecific anti-PD-L1/CTLA-4 antibody KN-046

Safety and tolerability data from first-in-human trial of GX-G6 as potential antidiabetic

Arvinas patents new IRAK-4-targeting compounds

Innovate Biopharmaceuticals initiates first ever phase III study in celiac disease

Topline data presented from phase II study of NYX-2925 in patients with fibromyalgia

Harvard College and Eisai divulge new compounds for cancer

Hepagene Therapeutics identifies MAP3K5 inhibitors

Merck & Co. synthesizes new IDO1 inhibitors

Homology Medicines initiates phase I/II study for HMI-102 gene therapy for adults with PKU

Northwestern University presents GBA activators

FDA approves first chemoimmunotherapy regimen for patients with DLBCL

Positive topline results presented for phase II study of Gazyva in lupus nephritis

Primary objective of safety achieved in the midpoint of first-in-human study of PKX-001

AVA-004 selected as clinical candidate for development in Avacta's Affimer PD-L1 inhibitor platform

Cognitive deficits ameliorated in mouse Alzheimer's models

PPC-06 meets both coprimary endpoints in phase IIb study in plaque psoriasis

Tree SLIT-tablet against allergic rhinitis approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...